Clinical trials: psoriasis
Psoriasis
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.
- Trial name
- NCT02387801
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Psoriasis
Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis
Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or placebo for the treatment of severe plaque psoriasis for 12 twelve weeks.
- Trial name
- NCT00716144
- Testing
- Talarozole
- Where
- 22 sites in Germany, Ireland and 3 more
- Volunteers
- 176 people
- Sponsor
- Stiefel, a GSK Company
Palmoplantaris Pustulosis
A Placebo-Controlled Double-Blind Study on the Safety and Efficacy of Etanercept in Palmoplantar Pustulosis
Palmoplantar pustulosis (PPP) is a chronic recurrent skin condition characterized by the presence of pustules, erythema and hyperkeratosis on palms and soles.
- Trial name
- NCT00353119
- Testing
- Etanercept
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- Innovaderm Research Inc.
Plaque Psoriasis
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
12 weeks open label with Otezla® and NUVB, followed by 6 month double blind Otezla® (apremilast) or placebo to subjects who obtain PASI 75 at week 12 of phototherapy
- Trial name
- NCT02412644
- Testing
- apremilast
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Plaque-type Psoriasis
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
The purpose of this study was to demonstrate efficacy of autoinjector administered secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- JUNCTURE (NCT01636687)
- Testing
- Secukinumab 150mg, Secukinumab 300mg
- Where
- 39 sites in United States, Canada and 3 more
- Volunteers
- 182 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01010542
- Testing
- ILV-095 300 mg in a 4 to 1 ratio
- Where
- 9 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis
The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT02899988
- Testing
- Mirikizumab
- Where
- 40 sites in United States, Canada and 4 more
- Volunteers
- 205 people
- Sponsor
- Eli Lilly and Company
Psoriatic Arthritis
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
- Trial name
- AMVISION-2 (NCT02024646)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 103 sites in United States, Canada and 8 more
- Volunteers
- 484 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
- Trial name
- NCT02407041
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Galectin Therapeutics Inc.
Psoriatic Arthritis
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
This study was designed to leverage the sensitivity of ultrasonography available in clinical practice setting to better describe the time course of response to secukinumab (150 mg and 300 mg) on joint synovitis and enthesitis in…
- Trial name
- PDUS (NCT02662985)
- Testing
- AIN457 (secukinumab)
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after…
- Trial name
- NCT04109976
- Testing
- Bimekizumab
- Where
- 47 sites in United States, Czechia and 4 more
- Volunteers
- 214 people
- Sponsor
- UCB Biopharma SRL
PSORIASIS
Etanercept and Vascular Function in Psoriasis
The investigators plan to measure the health of the vascular system of subjects taking Etanercept for the treatment of plaque psoriasis.
- Trial name
- EVIP (NCT01989689)
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Psoriatic Arthritis
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous…
- Trial name
- NCT01989468
- Testing
- Secukinumab
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment [IGA] score of 3 or 4).
- Trial name
- NCT02515097
- Testing
- IDP-122 Lotion, IDP-122 Vehicle Lotion
- Where
- 15 sites in United States
- Volunteers
- 213 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis
The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.
- Trial name
- NCT03924427
- Testing
- BMS-986165
- Where
- 27 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis
The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT03210259
- Testing
- Humira®, BI 695501
- Where
- 49 sites in United States, Germany and 5 more
- Volunteers
- 259 people
- Sponsor
- Boehringer Ingelheim
Psoriatic Arthritis
Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients
Dactylitis is a poor prognostic factor in psoriatic arthritis (PsA) patients. The efficacy of synthetic or biologic disease modifying anti-rheumatic drugs (DMARDs) on dactylitis has not been previously studied in randomized…
- Trial name
- GO-DACT (NCT02065713)
- Testing
- Golimumab, Methotrexate
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Instituto de Medicina Molecular João Lobo Antunes
Palmoplantar Psoriasis, Genital Psoriasis
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
- Trial name
- NCT06042920
- Testing
- Deucravacitinib
- Where
- 31 sites in United States, Argentina and 1 more
- Volunteers
- 130 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.
- Trial name
- NCT00245960
- Testing
- etanercept
- Where
- 120 sites in Argentina, Australia and 24 more
- Volunteers
- 752 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00678210
- Testing
- CP-690,550
- Where
- 44 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Pfizer